

Express Certificate

 ISIN: [AT0000A2VDC2](#) / WKN: RC05P2

chg. 1D	+1.180 (+1.91%)
Sell (Bid)	USD 62.340
Buy (Ask)	USD 63.840
Underlying price (indicative)	25.70 (+1.29%)
Next redemption level	47.44
Underlying	Pfizer Inc
Sustainability preference	Consideration of Principal Adverse Impacts (PAI)
Starting price underlying	USD 47.44
Barrier	USD 28.46
Distance to barrier	-
Observation barrier	on the final valuation date
(early) redemption level	47.44 / 47.44 / 47.44 / 47.44 / 47.44
Distance to next termination level	-84.58%
Max. yield until next observation date	>100%
Max. yield p.a. until next observation date	>100%
Underlying currency	USD
Valuation dates	Mar 07, 2023 / Mar 07, 2024 / Mar 06, 2025 / Mar 05, 2026 / Mar 04, 2027
(early) redemption amount	110.00% / 120.00% / 130.00% / 140.00% / 150.00%
Maturity date	Mar 10, 2027
Final valuation date	Mar 04, 2027
Issue date	Mar 09, 2022
Expected market trend	sideways, bullish
Listing	Stuttgart
Product currency	USD
Underlying currency	USD
Settlement method	Cash settlement / Physical delivery
Taxation	Capital Gains Tax

Last update: Jun 04, 2026, 7:59 pm

Description

This certificate provides the opportunity for early redemption each year and enables investors to obtain a yield of 10% per year if the price of the Pfizer share quotes on one of the annual valuation days at or above the termination level. In case the share price quotes below the respective termination level, the term will be extended by another year up to a maximum of 5 years. If the barrier is violated at the end of the term, the investor is entirely subject to market risk. This certificate complies with the **sustainability standard for Raiffeisen Certificates** and takes into account important adverse impacts on sustainability factors ("PAIs").

Price certificate (% of the starting value)



Price underlying (% of the starting value)



Distance to barrier

[Learn more about these charts](#)

Past performance is no reliable indicator of future results. Less than five years have passed since the launch of this certificate.



Effective as of 1 December 2022 Raiffeisen Centrobank AG has transferred its certificates business to Raiffeisen Bank International AG including (i) all associated rights and obligations, and (ii) the legal position as issuer of existing securities, i.e. outstanding securities issued by Raiffeisen Centrobank AG. Therefore, as of 1 December 2022, Raiffeisen Bank International AG constitutes the issuer of and the debtor under the securities referred to in the product brochure.

Please be aware that the product brochure reflects the legal situation at the date of its creation and does not contain any updated information about the issuer.

USD PFIZER EXPRESS 2

INVESTMENT PRODUCT WITHOUT CAPITAL PROTECTION
EXPRESS CERTIFICATE

- Underlying: Pfizer Inc. share
- Annual yield opportunity of 10%
- Barrier at 60% of the starting value, only active at the end of the term (share delivery possible)
- Full market risk in case of barrier violation, currency risk, issuer risk
- Further information on opportunities/risks on the following pages
- Term: 1 to 5 years (early redemption possible)



Certificates by

 **Raiffeisen
CENTROBANK**

REACH YOUR TARGET BY EXPRESS

In short:

The USD Pfizer Express 2 certificate offers an annual opportunity for early redemption, enabling investors to obtain a yield of 10% per year, if the Pfizer share quotes at or above its starting value at one of the valuation dates. If the share quotes below the starting value, the term extends by another year – up to a maximum of five years. In the event of a barrier violation at the final valuation date, the investor is entirely subject to market risk.

KEY FACTS

Issuer	Raiffeisen Centrobank AG*
Offer	continuous issuing
ISIN	AT0000A2VDC2
Issue price	100%
Nominal Value	USD 1,000
Subscription period ¹	Feb 8 - Mar 7, 2022
Initial valuation date	Mar 8, 2022
Issue value date	Mar 9, 2022
Annual valuation dates	Mar 7, 2023; Mar 7, 2024; Mar 6, 2025; Mar 5, 2026; Mar 4, 2027
Final valuation date	Mar 4, 2027
Early maturity dates	Mar 10, 2023; Mar 12, 2024; Mar 11, 2025; Mar 10, 2026
Maturity date	Mar 10, 2027
Starting value	closing price of the share at the initial valuation date
Termination level	100% of the starting value
Observation of the termination level	at each annual valuation date
Barrier	60% of the starting value
Observation of the barrier	only at the final valuation date
Redemption	Provided that the closing price of the Pfizer share quotes at or above the termination level at one of the annual valuation dates, (early) redemption is effected according to the predefined termination price. Otherwise redemption depends on the share performance: nominal value or shares. Redemption is dependent on the solvency of RCB*.
Listing	Vienna, Frankfurt, Stuttgart
Quotes	www.rcb.at

* Raiffeisen Centrobank AG is a 100% owned subsidiary of Raiffeisen Bank International AG – rating of RBI: www.rbinternational.com/ir/ratings

¹ Early closing or extension of the subscription period is within the sole discretion of Raiffeisen Centrobank AG.

FUNCTIONALITY

At the **initial valuation date**, the closing price of the Pfizer share is fixed as **starting value** and the **barrier** (60% of the starting value) is determined. The starting value also represents the **termination level**. At the respective **annual valuation date**, the **closing price of the Pfizer share is compared to the termination level**. If the share's closing price quotes at or above the termination level at one of the annual valuation dates, the certificate is redeemed at the predefined termination price:

TERM	TERMINATION LEVEL	TERMINATION PRICE	YIELD
1 st year:	100% = starting value	110% of the nominal value	1 x 10%
2 nd year:	100% = starting value	120% of the nominal value	2 x 10%
3 rd year:	100% = starting value	130% of the nominal value	3 x 10%
4 th year:	100% = starting value	140% of the nominal value	4 x 10%
5 th year:	100% = starting value	150% of the nominal value	5 x 10%

→ THE TERMINATION PRICE INCREASES WITH THE TERM

If the share quotes below the termination level at the annual valuation date, the term extends by another year (up to a maximum term of five years). At the same time, the **possible termination price increases annually by 10% of the nominal value** (up to a maximum of 150%).

If the certificate is not redeemed in the first four years and provided that the underlying quotes below the termination level at the fifth and **final valuation date**, an additional safety mechanism applies. If the share's closing price quotes above the barrier of 60% of the starting value, **redemption is effected at 100% of the nominal value**. This means that if the share price did not decline by 40% or more compared to the starting value by the end of the term, investors obtain the nominal value of USD 1,000 at the maturity date. If the closing price of the share is at or below the barrier at the final valuation date, **physical delivery of shares** is effected. This means the investor receives shares of Pfizer Inc. in the **amount predefined** at the initial valuation date (= nominal value/starting value). The difference to the next whole number is paid out.


Further details regarding opportunities and risks of this certificate are presented on the following page.

DEFINED NUMBER OF SHARES

The number of shares to be delivered is determined as follows: **number of shares = nominal value/starting value**
Usually this does not result in whole numbers. Due to the fact that shares are traded in whole numbers only, in the event of physical delivery the residual value is paid out in cash (= cash settlement) according to the market value: **fraction of the shares x closing price of the share at the final valuation date = cash settlement**

The **Pfizer Express 2** certificate provides for **physical delivery** of shares. In the most unfavourable case, the investor gets shares of Pfizer Inc. at the end of the term.

PFIZER INC.
ISIN: US7170811035



As of January 26, 2022; Source: Reuters (PFE).
Please note that past performance is no reliable indicator for future results.

RELEVANT STOCK EXCHANGE FOR THE UNDERLYING

Pfizer Inc.: New York Stock Exchange

SUITED MARKET EXPECTATION

declining

sideways

rising

YOUR INVESTMENT HORIZON

< 3 years

3 to 5 years


> 5 years

NOTE

The referenced opportunities and risks represent a selection of the most important facts regarding the product.

You are about to purchase a product that is not easy and difficult to understand.

For further information see the Base Prospectus (including possible amendments) – approved by the Austrian Financial Market Authority (FMA), deposited at the Oesterreichische Kontrollbank AG and published at www.rcb.at/en/securitiesprospectus (we recommend reading the prospectus before making an investment decision) –and the key information document as well as „Customer Information and Regulatory Issues“ at www.rcb.at/en/customerinformation



BARRIER AND CALCULATION OF THE NUMBER OF SHARES

SHARE	STARTING VALUE 100%*	BARRIER 60%	NUMBER OF SHARES = (nominal value/starting value)
Pfizer Inc.	USD 53.01	USD 31.806	18.8644 shares**

*... exemplary starting value based on the closing price of the Pfizer Inc. share as of Jan 26, 2022; Source: Reuters (PFE), ISIN: US7170811035; **... The fraction of the shares is paid out.

Currency risk/opportunity: This certificate is not currency hedged. If the cash flows from the certificate (repayment) are later converted into another currency, additional risks as well as opportunities arise from possible fluctuations of the currency price in relation to the nominal value.

OPPORTUNITIES

- **Yield opportunity:** Opportunity to obtain yield if the share price of Pfizer Inc. remains constant or increases.
- **Possible early redemption:** Early redemption at the predefined termination price if the share quotes at or above the termination level at one of the annual valuation dates.
- **Flexibility:** tradability on secondary market, no management fees

RISKS

- **Limited yield opportunity:** The maximum yield is limited to 10% per year. If the share of Pfizer Inc. does not quote at or above the termination level at any of the five valuation dates, no (early) redemption at the predefined termination price will be effected and investors will not obtain any yield.
- **Barrier violation:** If the barrier is violated at the final valuation date, investors receive Pfizer shares in the amount predefined and are entirely subject to market risk, without any protective mechanism. In the event of a physical delivery, the market value of the delivered shares will be less than the nominal value. Close to the barrier, disproportionate price movements of the certificate can also occur during the term.
- **Currency risk:** As the certificate is quoted in USD, there is a currency risk for Euro investors.
- **Issuer risk / Bail-in:** Certificates are not covered by the Deposit Protection Scheme. Investors are exposed to the risk that Raiffeisen Centrobank AG might be unable to fulfil its payment obligations in respect of the described financial instrument such as in the event of insolvency (issuer risk) or an official directive (Bail-in). A total loss of the capital invested is possible.

DISCLAIMER

In spite of all possible care taken, the data contained in this advertisement are provided purely as non-binding information. This advertisement constitutes neither investment advice nor an offer nor a recommendation nor an invitation to execute a transaction. The information contained in this advertisement is generic and no consideration is given to the personal circumstances of potential investors. The information contained in this advertisement substitutes neither the necessary individual investment advice for the purchase or sale of investments nor shall any investment decision be taken on the basis of this document. This advertisement has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to the prohibition on dealing ahead of the dissemination of investment research.

The complete information for all financial instruments described in this advertisement as well as the sole legal basis for potential transactions in one of the described financial instruments is the Base Prospectus (including any possible supplements) which has been approved by the Austrian Financial Market Authority (FMA) in connection with the corresponding Final Terms of the described financial instruments. The approved Base Prospectus (including any possible supplements) and the respective Final Terms have been deposited at the Oesterreichische Kontrollbank AG as the notification office. The approval of the Base Prospectus should not be construed as an endorsement of the financial instrument described herein by the FMA. Additional information on the financial instruments described herein may also be obtained from the respective key information documents (KIDs) that are available for download free of charge on the website of

Raiffeisen Centrobank AG (www.rcb.at) by entering the International Securities Identification Number (ISIN) of the respective financial instrument.

Unless otherwise explicitly expressed in any of the cited documents above, no measures have been taken in any national legal system which should permit a public offering of the products described therein. Raiffeisen Centrobank AG explicitly excludes any liability in relation to the correctness, appropriateness and completeness of the information presented herein.

Certificates are risky instruments of wealth investment. Should the price of the respective underlying instrument of a certificate develop adversely, an investor may lose part or all of his or her invested capital. Certificates react more strongly or weakly to changes of the price of the underlying instrument depending on a number of factors (e.g. volatility or correlation of the underlying instruments, interest, dividends, remaining term, changes in foreign exchange rates) and do not move simultaneously with the underlying. Under certain circumstances the issuer is authorized to redeem the certificates prior to the agreed repayment date. Issuer Risk/Creditor Participation ("bail-in"): Any payments during or at the end of the term of the certificates depend on the solvency of the issuer ("issuer risk"). Investors are therefore exposed to the risk that Raiffeisen Centrobank AG might be unable to fulfil its payment obligations in respect of the described financial instrument such as in the event of insolvency ("issuer risk") or an official directive ("bail-in"). The resolution authority may also issue such an order before any insolvency proceedings if the issuer is judged to be in crisis. Under these circumstances the resolution authority has wide-ranging powers to take action (so-called "bail-in instruments"). For example, it can reduce the claims of investors in respect of the described financial instruments to zero, terminate the described financial instruments, or convert them into shares of the issuer and suspend investors' rights. More detailed further information is available at www.rcb.at/en/basag. A total loss of the invested capital is possible.

Past performance is no reliable indicator of future results. Please refer to the Base Prospectus for additional disclosures on risks as well as further information.

The information presented does not constitute binding tax advice. Tax treatment of investments is dependent on the personal situation of the investor and may be subject to change. As regards tax treatment and impact on the investor's individual tax situation, the investor is advised to consult with a tax advisor. This report is based on the knowledge the persons preparing the document have obtained up to the date of creation. Please note that the legal situation may change due to legislative amendments, tax directives, opinions of financial authorities, jurisdiction etc.

The price of the Express Certificate is dependent on the underlying's price. Adverse performances of the underlying may cause price fluctuations of the Express Certificate. If the Express Certificate is sold, there is the risk to incur a substantial loss or even a total loss of the invested capital ("market risk"). The Express Certificate is subject to several influencing factors and need not develop simultaneously to and in accordance with the underlying's performance. Such influencing factors include e.g. intensity of the underlying's price fluctuations (volatility), interest rates, solvency of the issuer or remaining term. If the Express Certificate is sold prior to the end of the term, there is the risk to incur a partial or even total loss of the invested capital (price performance). Dividends and similar rights associated with the underlying are taken into account when structuring the Express Certificate and are not paid out.

Financial instruments denominated in a currency that is not the official currency of the country of residence of the potential investor (e.g. denominated in USD) expose the potential investor to a supplementary currency risk that may adversely affect the performance of these financial instruments.

Certificates issued by RCB are no financial products as defined in the Regulation (EU) 2019/2088.

Supervisory Authorities: Austrian Financial Market Authority (FMA), Austrian National Bank, European Central Bank within the Single Supervisory Mechanism (SSM). Imprint according to the Austrian Media Act: Media Owner and Publisher is Raiffeisen Centrobank AG | Member of RBI Group | Am Stadtpark 9, 1030 Vienna/Austria.

Further information may be obtained from the consultant at your local bank, on the Internet at www.rcb.at or on the product hotline of Raiffeisen Centrobank AG: +43 1/51520 - 484.

Your contacts at Raiffeisen Centrobank AG, Am Stadtpark 9, 1030 Vienna/Austria:

Product Hotline	Ph: +43 1/51520 - 484	produkte@rcb.at
Heike Arbter (Member of the Board)	Ph: +43 1/51520 - 407	heike.arbter@rcb.at
Philipp Arnold (Head of Structured Products Sales)	Ph: +43 1/51520 - 469	philipp.arnold@rcb.at
Roman Bauer (Head of Trading)	Ph: +43 1/51520 - 384	roman.bauer@rcb.at
Mariusz Adamiak	Ph: +43 1/51520 - 395	mariusz.adamiak@rcb.at
Raphael Bischinger	Ph: +43 1/51520 - 432	raphael.bischinger@rcb.at
Maida Blentic	Ph: +43 1/51520 - 394	maida.blentic@rcb.at
Anton Bondar	Ph: +43 1/51520 - 471	anton.bondar@rcb.at
Peidong Cao	Ph: +43 1/51520 - 493	peidong.cao@rcb.at
Lukas Florreither	Ph: +43 1/51520 - 397	lukas.florreither@rcb.at
Walter Friehsinger	Ph: +43 1/51520 - 392	walter.gollner@rcb.at
Levin Gollner, MA	Ph: +43 1/51520 - 473	levin.hackl@rcb.at
Lukas Hackl	Ph: +43 1/51520 - 468	lukas.hackl@rcb.at
Jan Kausek	Ph: +43 1/51520 - 486	jan.kausek@rcb.at
Kathrin Korinek	Ph: +43 1/51520 - 401	kathrin.korinek@rcb.at
Jaroslav Kysela	Ph: +43 1/51520 - 481	jaroslav.kysela@rcb.at
Aleksandar Makuljevic	Ph: +43 1/51520 - 385	aleksandar.makuljevic@rcb.at
Monika Mrnustikova	Ph: +43 1/51520 - 386	monika.mrnustikova@rcb.at
Anja Niederreiter	Ph: +43 1/51520 - 483	anja.niederreiter@rcb.at
Michal Polin	Ph: +421/257203 - 041	michal.polin@rcb.sk
Martin Rainer	Ph: +43 1/51520 - 391	martin.rainer@rcb.at
Gabriele Rihtar	Ph: +43 1/51520 - 379	gabriele.rihtar@rcb.at
Ludwig Schweighofer	Ph: +43 1/51520 - 460	ludwig.schweighofer@rcb.at
Johanna Stich	Ph: +43/51520 - 351	johanna.stich@rcb.at
Andreas Tosch	Ph: +43/51520 - 470	andreas.tosch@rcb.at
Alexander Unger	Ph: +43 1/51520 - 478	alexander.unger@rcb.at
Fabiola Vicenova	Ph: +421/257203 - 040	fabiola.vicenova@rcb.sk
Martin Vonwald	Ph: +43 1/51520 - 338	martin.vonwald@rcb.at
Wilhelmine Wagner-Freudenthal	Ph: +43 1/51520 - 381	wilhelmine.wagner-freudenthal@rcb.at



Certificates by



**Raiffeisen
CENTROBANK**